Literature DB >> 1885214

Identification of a 200-kDa glycoprotein antigen of Saccharomyces cerevisiae.

B T Heelan1, S Allan, R M Barnes.   

Abstract

SDS-PAGE analysis of the soluble proteins of the yeast Saccharomyces cerevisiae revealed a single predominant moiety of apparent size 200 kDa which was strongly periodic acid Schiff-positive. In immunoblotting experiments, human sera containing anti-S. cerevisiae antibodies were reactive only with this glycoprotein (gp200); this was demonstrated using sera containing IgG and IgA isotype-specific anti-S. cerevisiae antibodies. The antigenicity of gp200 was substantially reduced by periodate treatment. These results show that gp200 is a major glycoprotein antigen of S. cerevisiae which is immunogenic in man.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1885214     DOI: 10.1016/0165-2478(91)90001-q

Source DB:  PubMed          Journal:  Immunol Lett        ISSN: 0165-2478            Impact factor:   3.685


  12 in total

1.  Utility of fecal and serum anti-Saccharomyces cerevisiae antibodies in the diagnosis of Crohn's disease-like condition of the pouch.

Authors:  Linda Y Tang; Hui Cai; Udayakumar Navaneethan; James H Boone; Sarah J Rhodes; Lauren Moore; Hyunjin Rho; Carol de La Motte; Elaine Queener; Bo Shen
Journal:  Int J Colorectal Dis       Date:  2012-03-20       Impact factor: 2.571

2.  Anti-Saccharomyces cerevisiae and antineutrophil cytoplasmic antibodies as predictors of inflammatory bowel disease.

Authors:  E Israeli; I Grotto; B Gilburd; R D Balicer; E Goldin; A Wiik; Y Shoenfeld
Journal:  Gut       Date:  2005-09       Impact factor: 23.059

3.  Circulating antibodies to Saccharomyces cerevisiae (bakers'/brewers' yeast) in gastrointestinal disease.

Authors:  C J Darroch; R M Barnes; J Dawson
Journal:  J Clin Pathol       Date:  1999-01       Impact factor: 3.411

4.  Specific antibody response to oligomannosidic epitopes in Crohn's disease.

Authors:  B Sendid; J F Colombel; P M Jacquinot; C Faille; J Fruit; A Cortot; D Lucidarme; D Camus; D Poulain
Journal:  Clin Diagn Lab Immunol       Date:  1996-03

Review 5.  Current understanding of fungal microflora in inflammatory bowel disease pathogenesis.

Authors:  David Underhill; Jonathan Braun
Journal:  Inflamm Bowel Dis       Date:  2008-08       Impact factor: 5.325

6.  Seroreactivity against Saccharomyces cerevisiae in patients with Crohn's disease and celiac disease.

Authors:  Zsolt Barta; István Csípõ; Gábor G Szabó; Gyula Szegedi
Journal:  World J Gastroenterol       Date:  2003-10       Impact factor: 5.742

7.  Serum and salivary IgA antibody responses to Saccharomyces cerevisiae, Candida albicans and Streptococcus mutans in orofacial granulomatosis and Crohn's disease.

Authors:  N W Savage; K Barnard; P J Shirlaw; D Rahman; M Mistry; M P Escudier; J D Sanderson; S J Challacombe
Journal:  Clin Exp Immunol       Date:  2004-03       Impact factor: 4.330

8.  Characterization of oligosaccharides from an antigenic mannan of Saccharomyces cerevisiae.

Authors:  M Young; M J Davies; D Bailey; M J Gradwell; B Smestad-Paulsen; J K Wold; R M Barnes; E F Hounsell
Journal:  Glycoconj J       Date:  1998-08       Impact factor: 2.916

Review 9.  Utility of serological markers in inflammatory bowel diseases: gadget or magic?

Authors:  Maria Papp; Gary L Norman; Istvan Altorjay; Peter Laszlo Lakatos
Journal:  World J Gastroenterol       Date:  2007-04-14       Impact factor: 5.742

10.  IgG and IgE immune response against the surface glycoprotein gp200 of Saccharomyces cerevisiae in patients with atopic dermatitis.

Authors:  P Nenoff; B Müller; U Sander; G Kunze; M Bröker; U F Haustein
Journal:  Mycopathologia       Date:  2001       Impact factor: 3.785

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.